Revelation Partners — 2023 Investments

1 investments dated 2023 · listed companies and verified rows first · show all

Nouscomnouscom.comNov 2023

Immunotherapy company developing NOUS-209 for the prevention of Lynch syndrome-associated cancers.

Co-investors5AM Ventures Andera Partners Angelini Ventures CDP Venture Capital Indaco Venture Partners M Ventures +5 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.